glp 1 neurotransmitter The Multifaceted Nature of GLP-1: Molecular Mechanisms and Signaling Pathways in Metabolic and Neurodegenerative Diseases GLP-1 Analogues in the Neurobiology

The key differences between brand-name and compounded GLP-1 medications come down to cost, format, and regulatory status

doi: 10.2337/db22-0745

Emerging preclinical and clinical evidence suggests these medications may modulate reward-seeking behaviour and reduce the reinforcing effects of alcohol, though this remains an area of active investigation rather than established clinical practice

Importantly, no significant side effects were recorded, providing proof of concept for GLP-1 therapy in subjects with T2D

By 2030, biosimilars will capture 20-30% of the semaglutide market, forcing Novo Nordisk to reduce Wegovy pricing by 15-25%

12 Another limitation is the variability of the available literature, which includes different research designs (RCTs, cohorts, casecontrol studies)